{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T21:40:25Z","timestamp":1718401225125},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clin Oncol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1111\/ajco.12485","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T10:17:28Z","timestamp":1457345848000},"page":"259-264","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients"],"prefix":"10.1111","volume":"12","author":[{"given":"Yoshinori","family":"Makino","sequence":"first","affiliation":[{"name":"Department of Pharmacy; National Cancer Center Hospital; Tokyo Japan"},{"name":"Division of Pharmacokinetics\/Pharmacodynamics; Department of Pharmacotherapy; School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; National Cancer Center Hospital; Tokyo Japan"},{"name":"Division of Pharmacokinetics\/Pharmacodynamics; Department of Pharmacotherapy; School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko Ando","family":"Makihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; National Cancer Center Hospital; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Division of Pharmacokinetics\/Pharmacodynamics; Department of Pharmacotherapy; School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Pharmacokinetics\/Pharmacodynamics; Department of Pharmacotherapy; School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; National Cancer Center Hospital; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"10.1111\/ajco.12485-BIB0001|ajco12485-cit-0001","first-page":"866","article-title":"The SM-5887 lung cancer study group: A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small-cell lung cancer","author":"Hiraki","year":"1993","journal-title":"Proceedings of the 18th International Congress of Chemotherapy"},{"key":"10.1111\/ajco.12485-BIB0002|ajco12485-cit-0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10637-006-5937-2","article-title":"Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial","volume":"24","author":"Sawa","year":"2006","journal-title":"Investig New Drugs"},{"key":"10.1111\/ajco.12485-BIB0003|ajco12485-cit-0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10637-006-9012-9","article-title":"Phase II study of amrubicin in previously untreated patients with extensive disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study","volume":"25","author":"Yana","year":"2007","journal-title":"Investig New Drugs"},{"key":"10.1111\/ajco.12485-BIB0004|ajco12485-cit-0004","first-page":"379s","article-title":"Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)","volume":"24","author":"Kato","year":"2006","journal-title":"2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)"},{"key":"10.1111\/ajco.12485-BIB0005|ajco12485-cit-0005","first-page":"1055","article-title":"In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite","volume":"89","author":"Noguchi","year":"1998","journal-title":"J Cancer Res"},{"key":"10.1111\/ajco.12485-BIB0006|ajco12485-cit-0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.ftd.0000185771.82620.ee","article-title":"Pharmacokinetics of amrubicin and amrubicinol in lung cancer patients","volume":"28","author":"Matsunaga","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1111\/ajco.12485-BIB0007|ajco12485-cit-0007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00280-005-0051-2","article-title":"Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer","volume":"57","author":"Okamoto","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/ajco.12485-BIB0008|ajco12485-cit-0008","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/CAD.0b013e32832b0585","article-title":"Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities","volume":"20","author":"Kimura","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1111\/ajco.12485-BIB0009|ajco12485-cit-0009","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-011-1768-8","article-title":"Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer","volume":"69","author":"Makino","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/ajco.12485-BIB0010|ajco12485-cit-0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/157339409787314081","article-title":"Utility of limited sampling strategies for anticancer agents in the clinical arena: A systematic review","volume":"5","author":"Pattar","year":"2009","journal-title":"Curr Cancer Therapy Rev"},{"key":"10.1111\/ajco.12485-BIB0011|ajco12485-cit-0011","unstructured":"Petrov B Csaki F Akaike H Information theory and an extension of the maximum likelihood principle"},{"key":"10.1111\/ajco.12485-BIB0012|ajco12485-cit-0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bmc.1289","article-title":"Simple and sensitive HPLC method for determination of amrubicin and amrubicinol in human plasma: Application to a clinical pharmacokinetic study","volume":"24","author":"Ando","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"10.1111\/ajco.12485-BIB0013|ajco12485-cit-0013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01240143","article-title":"Limited-sampling models for anticancer agents","volume":"120","author":"Warmerdam","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/ajco.12485-BIB0014|ajco12485-cit-0014","first-page":"117","article-title":"A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38","volume":"86","author":"Sasaki","year":"1995","journal-title":"J Cancer Res"},{"key":"10.1111\/ajco.12485-BIB0015|ajco12485-cit-0015","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.1996.14.7.2012","article-title":"Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity","volume":"14","author":"Mick","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12485-BIB0016|ajco12485-cit-0016","first-page":"1087","article-title":"Limited sampling models for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial","volume":"3","author":"Yamamoto","year":"1997","journal-title":"Clin Cancer Res"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12485","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajco.12485\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T21:03:50Z","timestamp":1718399030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12485"}},"subtitle":["Optimize limited sampling points of Amrubicin"],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"URL":"https:\/\/doi.org\/10.1111\/ajco.12485","archive":["Portico"],"relation":{},"ISSN":["1743-7555"],"issn-type":[{"value":"1743-7555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,7]]}}}